Files in this Data Supplement:

• Figure I - (Microsoft PowerPoint) (67.5 kb). Effects of TRPV1 receptor ablation on cardiac function during ischemia and reperfusion. TRPV1^-/- and WT hearts were retrogradely perfused in a Langendorff apparatus and then subjected to no-flow ischemia, followed by reperfusion with or without capsazepine (CAPZ) (WTi, WTi+CAPZ, TRPV1^-/-i, TRPV1^-/-i+CAPZ). As controls, WT, TRPV1^-/-, and WT+CAPZ hearts were perfused throughout the 95-minute period without ischemia (WTn, TRPV1^-/-n, WTn+CAPZ). A, Left ventricular end-diastolic pressure (LVEDP). B, Left ventricular developed pressure (LVDP). C, Coronary flow (CF). Values are mean±SEM; *P<0.05 WT hearts subjected to I/R injury (WTi) vs TRPV1^-/- hearts subjected to I/R injury (TRPV1^-/-i); †P<0.05 TRPV1^-/-i vs WTi+CAPZ hearts; ‡P<0.05 WTi vs WTi+CAPZ hearts.
• Figure II - Microsoft PowerPoint) (65.0 kb). Effects of CGRP on cardiac function during ischemia and reperfusion. TRPV1^-/- and WT hearts were subjected to the same ischemia-reperfusion protocol described in Figure I and WTi and TRPV1^-/-i represent the same animals as in Figure I. CGRP was added to perfusate 5 minutes before ischemia and CGRP8-37 was added 5 minutes before adding CGRP. A, Left ventricular end-diastolic pressure (LVEDP). B, Left ventricular developed pressure (LVDP). C, Coronary flow(CF). Values are mean±SEM; *P<0.05 WTi vs TRPV1^-/-i; †P<0.05 TRPV1^-/-i vs TRPV1^-/-i+CGRP; ‡P<0.05 WTi vs WTi+CGRP.
• Figure III - (Microsoft PowerPoint) (64.0 kb). Effects of CGRP receptor antagonist CGRP8-37 on cardiac function during ischemia and reperfusion. TRPV1^-/- and WT hearts were subjected to the same ischemia-reperfusion protocol described in Figure I and WTi and TRPV1^-/-i represent the same animals as in Figure I. CGRP8-37 was added to perfusate 5 minutes before ischemia. A, Left ventricular end-diastolic pressure (LVEDP). B, Left ventricular developed pressure (LVDP). C, Coronary flow (CF). Values are mean±SEM; *P<0.05 WTi vs TRPV1^-/-i.
• Figure IV - (Microsoft PowerPoint) (65.0 kb). Effects of sunstance P (SP) on cardiac function during ischemia and reperfusion. TRPV1^-/- and WT hearts were subjected to the same ischemia-reperfusion protocol described in Figure I and WTi and TRPV1^-/-i represent the same animals as in Figure I. SP was added to perfusate 5 minutes before ischemia and RP67580 was added to perfusate 5 minutes before adding SP. A, Left ventricular end-diastolic pressure (LVEDP). B, Left ventricular developed pressure (LVDP). C, Coronary flow (CF). Values are mean±SEM; *P<0.05 WTi vs TRPV1^-/-i; †P<0.05 TRPV1^-/-i vs TRPV1^-/-i+SP hearts; ‡P<0.05 WTi vs WTi+SP; #P<0.05 WTi+SP vs TRPV1^-/-i+SP hearts.
• Figure V - (Microsoft PowerPoint) (64.0 kb). Effects of sunstance P receptor antagonist RP67580 (RP) on cardiac function during ischemia and reperfusion. TRPV1^-/- and WT hearts were subjected to the same ischemia-reperfusion protocol described in Figure I and WTi and TRPV1^-/-i represent the same animals as in Figure I. RP67580 was added to perfusate 5 minutes before ischemia. A, Left ventricular end-diastolic pressure (LVEDP). B, Left ventricular developed pressure (LVDP). C, Coronary flow (CF). Values are mean±SEM; *P<0.05 WTi vs TRPV1^-/-i; †P<0.05 TRPV1^-/-i vs TRPV1^-/-i+RP hearts; ‡P<0.05 WTi vs WTi+RP.